Stories

This Feature Includes: Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data.

Successful implementation of a new slide scanning and analysis platform across five laboratories represents a significant step forward in Mayo Clinic’s digital pathology program — an initiative that combines advanced technology with human expertise to better serve patients.

This week’s research roundup features: Androgen deprivation therapy use and duration with definitive radiotherapy for localized prostate cancer: an individual patient data meta-analysis.

A Mayo Clinic Laboratories newborn screening panel detects a rare disease and paves the way for life-sustaining treatment.

Topic's Include: Mayo Clinic Q&A podcast: New cases of COVID-19 continue downward trend.

As a client account representative, Heather Van Buskirk uses her problem-solving skills to make sure invoices get paid in a timely manner, so Mayo Clinic Laboratories’ services remain available to providers and their patients.

This week’s research roundup features: Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: An ECOG-ACRIN cancer research group trial (E3311).

Topic's Include: Mayo Clinic expert discusses how COVID-19 vaccination during pregnancy may protect babies after birth, and Mayo Clinic in Rochester to ease visitor restrictions for hospital patients.

This week’s research roundup features: Deep residual inception encoder-decoder network for amyloid PET harmonization.

Topic's Include: Cases down, but Mayo Clinic expert says COVID-19 pandemic isn’t over, and community leaders and Mayo Clinic researchers develop playbook for COVID-19 health equity, future pandemics.

As director of Contract Administration, Cara Ryan’s work spans a diverse range of activities that connect with a variety of groups across the organization, all with a goal of supporting patient care.

This week’s research roundup features: Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.

Topic's Include: Mayo Clinic in Rochester eases visitor restrictions for pediatric hospital patients, and ask the Mayo Mom: More than 2 years of COVID-19 takes its toll on children, families.